Clinical Commander

Back to dossier
cardio.cardiac-tamponade.effusive-constrictive.v1PRODUCTION
cardio.cardiac-tamponade.effusive-constrictive.v1

Cardiac tamponade — effusive-constrictive pericarditis (Sagristà-Sauleda syndrome)

cardiologyacuteadult
Hard-required inputs
0 / 9
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Effusive-constrictive pericarditis = effusion + tamponade + persistent constrictive physiology after drainage; pericardiocentesis relieves the effusion but residual visceral constriction persists; definitive therapy is anti-inflammatory + etiology-specific Rx OR pericardiectomy if chronic/refractory (Sagristà-Sauleda NEJM 2004 PMID 15128896; ESC 2015)

Inputs
1
Actions
0
Advance rule
Set
Advance when

effusive-constrictive physiology suspected on echo

Patient inputs (9)

Pericardial thickness >4 mm + late gadolinium enhancement of visceral pericardium identifies constriction substrate + active inflammation (steroid-responsive vs fibrotic-irreversible) (Klein JASE 2013; ESC 2015)

Older patients have higher pericardiectomy operative mortality + competing comorbidities; younger patients tolerate visceral peel better

Compensatory tachycardia in tamponade physiology (ESC 2015)

Etiology drives definitive therapy choice — TB requires RIPE, autoimmune requires immunosuppression, malignancy requires oncologic therapy, radiation suggests fibrotic/irreversible substrate

Definitive bedside dx — chamber collapse, IVC, swinging heart; SPECIFIC features of effusive-constrictive (septal bounce, restrictive mitral inflow with >25% E-wave respiratory variation, annulus reversus on tissue Doppler) (Klein JASE 2013; ESC 2015)

eGFR for contrast cardiac MRI gadolinium decision + perioperative renal risk if pericardiectomy planned

Inflammation markers — high CRP suggests active inflammatory effusive-constrictive amenable to anti-inflammatory therapy; persistently elevated despite NSAID/colchicine is a treatment-failure signal (ICAP PMID 23992557)

Hypotension is part of Beck triad; pulsus paradoxus measurement (Spodick Circulation 2003)

GOLD STANDARD diagnostic — simultaneous RA + LV/PCWP measurements pre- and post-pericardiocentesis. Defining feature: RA pressure fails to fall ≥50% or to <10 mmHg after intrapericardial pressure normalizes (Sagristà-Sauleda NEJM 2004 PMID 15128896)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningpost_drain_decompensation_from_residual_constriction
    After pericardiocentesis evacuates fluid, hemodynamic decompensation occurs — residual visceral constriction limits diastolic filling; clinical correlate of effusive-constrictive physiology that requires bridging therapy + urgent cardiothoracic surgery evaluation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepersistent_constrictive_physiology_post_drainage
    After pericardiocentesis, RA pressure fails to fall ≥50% or to <10 mmHg despite normalisation of intrapericardial pressure → effusive-constrictive physiology confirmed (Sagristà-Sauleda NEJM 2004 PMID 15128896)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepericardiectomy_decision_in_radiation_field
    Radiation-induced effusive-constrictive pericarditis with persistent symptoms — radiation substrate is typically fibrotic and irreversible; pericardiectomy operative mortality is HIGHER in radiation field (mediastinal fibrosis, vascular adhesions); requires careful surgical evaluation by experienced pericardial surgery team
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveretb_co_infection_management_in_effusive_constrictive
    TB pericarditis presenting as effusive-constrictive — most common etiology globally per Mayosi Heart 2017; requires 4-drug RIPE × 6 mo + adjunctive prednisolone IF HIV-NEGATIVE per IMPI; pericardiectomy decision typically deferred until 4-6 mo of RIPE unless decompensated
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_effusion_despite_drainage_and_anti_inflammatory_therapy
    Re-accumulation of pericardial effusion despite drainage + NSAID + colchicine + etiology-specific therapy — suggests treatment-resistant inflammation OR alternative etiology missed (occult malignancy, TB, autoimmune)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Effusive-constrictive pericarditis — pericardiocentesis + invasive hemodynamics + NSAID/colchicine + etiology-specific Rx + pericardiectomy decision (Sagristà-Sauleda NEJM 2004 PMID 15128896; ESC 2015; ICAP PMID 23992557)
axis: effusive_constrictive_drainage_plus_anti_inflammatory_plus_etiology_specific
Selected axis "Effusive-constrictive pericarditis — pericardiocentesis + invasive hemodynamics + NSAID/colchicine + etiology-specific Rx + pericardiectomy decision (Sagristà-Sauleda NEJM 2004 PMID 15128896; ESC 2015; ICAP PMID 23992557)" by default fallback (first axis)
  • ibuprofen
    first line
    nsaid_propionic
    600-800 mg PO TID × 1-2 wk then taper • PO • TID × 2 wk + taper
    triggers: inflammatory_effusive_constrictive_pericarditis_active_disease
    ICAP/CORP (Imazio NEJM 2013 PMID 23992557) — first-line for inflammatory pericarditis; eGFR + GI bleed risk gate use
    rxcui 5640
  • aspirin
    first line
    nsaid_salicylate
    750-1000 mg PO TID × 1-2 wk then taper • PO • TID × 2 wk + taper
    triggers: post_mi_pericarditis_or_dressler_inflammatory_etiology
    Preferred NSAID if post-MI Dressler etiology (does not impair ventricular remodeling like ibuprofen)
    rxcui 1191
  • colchicine
    first line
    microtubule_inhibitor
    0.6 mg PO BID (≥70 kg) or 0.6 mg daily (<70 kg) × 3 mo for first episode; × 6 mo for recurrent • PO • BID × 3-6 mo
    triggers: inflammatory_effusive_constrictive_pericarditis_to_prevent_fibrosis_and_recurrence
    ICAP (Imazio NEJM 2013 PMID 23992557) + CORP (Imazio Ann Intern Med 2011) + CORP-2 (Imazio Lancet 2014) — colchicine reduces recurrence + fibrosis; renal dose-adjust
    rxcui 2683
  • prednisolone
    second line
    corticosteroid
    0.2-0.5 mg/kg/day PO with slow taper over months • PO • daily, slow taper
    triggers: nsaid_intolerant_or_contraindicated, autoimmune_etiology, tb_etiology_if_hiv_negative_per_impi
    ESC 2015 — reserve for NSAID-intolerant or autoimmune; LOW dose preferred (high-dose steroids associated with recurrence); IMPI Mayosi NEJM 2014 PMID 25199187 — adjunctive in HIV-NEGATIVE TB
    rxcui 8638
  • methotrexate
    rescue
    antimetabolite_dmard
    10-15 mg PO weekly + folic acid • PO • weekly
    triggers: recurrent_pericarditis_refractory_to_NSAID_colchicine_steroid, rheumatologic_etiology
    ESC 2015 + small case series — corticosteroid-sparing for recurrent pericarditis
    rxcui 6851
  • normal saline
    first line
    isotonic_crystalloid
    500-1000 mL bolus • IV • rapid bolus then reassess
    triggers: hypotension_pre_drainage
    Bridge preload to drainage (ESC 2015)
    rxcui 9863
  • norepinephrine
    rescue
    vasopressor
    0.05-0.1 µg/kg/min titrate to MAP ≥65 • IV • continuous
    triggers: SBP_lt_85_despite_fluids, post_drain_decompensation_from_residual_constriction
    Bridge only — does not address obstruction (Roy JAMA 2007); persistent need post-drain raises suspicion for residual constriction
    rxcui 7512
  • furosemide
    add on
    loop_diuretic
    20-40 mg PO daily titrate • PO • daily
    triggers: post_drain_residual_constriction_with_volume_overload, symptomatic_chronic_constriction_pre_pericardiectomy
    Symptomatic relief while pericardiectomy evaluated; does NOT address constriction physiology (ESC 2015)
    rxcui 4603

outpatient playbook — drug actions (4)

  1. 1. taper NSAID per CRP normalisation
    rxcui 5640
    ibuprofen taper to 400 mg BID then off when CRP normal × 4 wk • PO • taper
    trigger: Inflammation resolved
    ICAP (Imazio PMID 23992557)
  2. 2. complete colchicine course
    rxcui 2683
    colchicine 0.6 mg PO BID × 3 mo first episode, × 6 mo recurrent • PO • BID
    trigger: Per CORP/CORP-2
    CORP-2 (Imazio Lancet 2014)
  3. 3. complete etiology-specific therapy
    RIPE × 6 mo if TB; immunosuppression maintenance if autoimmune • PO/IV • per regimen
    trigger: Etiology-specific course
    WHO 2024 / ACR 2021
  4. 4. diuretic for symptomatic constriction pre-pericardiectomy
    rxcui 4603
    furosemide 20-40 mg PO daily titrate • PO • daily
    trigger: Symptomatic constriction with volume overload
    ESC 2015 — symptomatic relief while pericardiectomy evaluated

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Echo: pericardial effusion with tamponade physiology PLUS septal bounce + restrictive mitral inflow + dilated non-collapsing IVC suggesting underlying constriction (Klein JASE 2013; Sagristà-Sauleda NEJM 2004 PMID 15128896); Beck triad → pericardiocentesis → JVD persists + IVC remains plethoric → effusive-constrictive physiology suspected; obtain post-drain hemodynamics; Pericarditis with persistent CRP elevation despite NSAID + colchicine + new pericardial effusion → inflammatory effusive-constrictive (ESC 2015 §3.5).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiac tamponade — effusive-constrictive pericarditis (Sagristà-Sauleda syndrome)** (cardio.cardiac-tamponade.effusive-constrictive.v1).
Scope: Effusive-constrictive pericarditis = effusion + tamponade + persistent constrictive physiology after drainage; pericardiocentesis relieves the effusion but residual visceral constriction persists; definitive therapy is anti-inflammatory + etiology-specific Rx OR pericardiectomy if chronic/refractory (Sagristà-Sauleda NEJM 2004 PMID 15128896; ESC 2015)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Effusive-constrictive pericarditis — pericardiocentesis + invasive hemodynamics + NSAID/colchicine + etiology-specific Rx + pericardiectomy decision (Sagristà-Sauleda NEJM 2004 PMID 15128896; ESC 2015; ICAP PMID 23992557)**.
1. ibuprofen 600-800 mg PO TID × 1-2 wk then taper PO TID × 2 wk + taper (nsaid_propionic, first line) — ICAP/CORP (Imazio NEJM 2013 PMID 23992557) — first-line for inflammatory pericarditis; eGFR + GI bleed risk gate use
2. aspirin 750-1000 mg PO TID × 1-2 wk then taper PO TID × 2 wk + taper (nsaid_salicylate, first line) — Preferred NSAID if post-MI Dressler etiology (does not impair ventricular remodeling like ibuprofen)
3. colchicine 0.6 mg PO BID (≥70 kg) or 0.6 mg daily (<70 kg) × 3 mo for first episode; × 6 mo for recurrent PO BID × 3-6 mo (microtubule_inhibitor, first line) — ICAP (Imazio NEJM 2013 PMID 23992557) + CORP (Imazio Ann Intern Med 2011) + CORP-2 (Imazio Lancet 2014) — colchicine reduces recurrence + fibrosis; renal dose-adjust
4. prednisolone 0.2-0.5 mg/kg/day PO with slow taper over months PO daily, slow taper (corticosteroid, second line) — ESC 2015 — reserve for NSAID-intolerant or autoimmune; LOW dose preferred (high-dose steroids associated with recurrence); IMPI Mayosi NEJM 2014 PMID 25199187 — adjunctive in HIV-NEGATIVE TB
5. methotrexate 10-15 mg PO weekly + folic acid PO weekly (antimetabolite_dmard, rescue) — ESC 2015 + small case series — corticosteroid-sparing for recurrent pericarditis
6. normal saline 500-1000 mL bolus IV rapid bolus then reassess (isotonic_crystalloid, first line) — Bridge preload to drainage (ESC 2015)
7. norepinephrine 0.05-0.1 µg/kg/min titrate to MAP ≥65 IV continuous (vasopressor, rescue) — Bridge only — does not address obstruction (Roy JAMA 2007); persistent need post-drain raises suspicion for residual constriction
8. furosemide 20-40 mg PO daily titrate PO daily (loop_diuretic, add on) — Symptomatic relief while pericardiectomy evaluated; does NOT address constriction physiology (ESC 2015)

Setting playbook (outpatient) — Long-term surveillance + pericardiectomy decision at 3-6 mo if refractory; etiology-specific therapy completion; NSAID/colchicine taper per ICAP; serial echo + cardiac MRI; multidisciplinary continuation (ESC 2015; Sagristà-Sauleda NEJM 2004 PMID 15128896)
9. taper NSAID per CRP normalisation ibuprofen taper to 400 mg BID then off when CRP normal × 4 wk PO taper — Inflammation resolved (ICAP (Imazio PMID 23992557))
10. complete colchicine course colchicine 0.6 mg PO BID × 3 mo first episode, × 6 mo recurrent PO BID — Per CORP/CORP-2 (CORP-2 (Imazio Lancet 2014))
11. complete etiology-specific therapy RIPE × 6 mo if TB; immunosuppression maintenance if autoimmune PO/IV per regimen — Etiology-specific course (WHO 2024 / ACR 2021)
12. diuretic for symptomatic constriction pre-pericardiectomy furosemide 20-40 mg PO daily titrate PO daily — Symptomatic constriction with volume overload (ESC 2015 — symptomatic relief while pericardiectomy evaluated)

Non-pharmacologic actions:
- Cardiology follow-up at 1, 3, 6, 12 mo then annually × 5 yr
- Cardiothoracic surgery follow-up at 3 mo + 6 mo for pericardiectomy decision
- Etiology-specific specialist follow-up per disease
- Cardiac MRI at 3 mo + 12 mo + as indicated
- Patient + family education ongoing for adherence + warning signs
- Cardiac rehab if functional decline

AVOID / contraindication checks:
- Positive_pressure_ventilation_AVOID_pre_drain (ESC 2015)
- NSAID_avoid_severe_renal_impairment_egfr_below_30_or_active_GI_bleed (drug labels)
- High_dose_steroids_AVOID_in_inflammatory_pericarditis_increases_recurrence (ESC 2015)
- Steroids_AVOID_in_HIV_positive_TB_pericarditis_per_IMPI_subgroup (Mayosi NEJM 2014 PMID 25199187)
- Colchicine_renal_dose_adjust_avoid_with_strong_cyp3a4_inhibitors (drug label)
- Gadolinium_avoid_if_eGFR_below_30_unless_group_II_macrocyclic (FDA 2018)
- Decision:pericardiectomy_for_chronic_refractory_constriction_after_3_to_6_mo_failed_medical_therapy (ESC 2015 Class IIa)
- Decision:pericardiectomy_visceral_peel_higher_operative_mortality_5_to_15_pct_than_parietal_alone (Murashita JTCVS)
- Decision:radiation_substrate_typically_fibrotic_irreversible_consider_pericardiectomy_earlier (ESC 2015)
- Decision:tb_etiology_complete_RIPE_4_to_6_mo_before_pericardiectomy_decision_unless_decompensated (WHO TB 2024; ESC 2015)

Monitoring

Regimen monitoring:
- continuous ECG during drainage (ESC 2015)
- art line BP pre and post drain with simultaneous RA LV PCWP (Sagristà-Sauleda NEJM 2004 PMID 15128896)
- echo post drain immediate then q24 48h x 7d then weekly x 4 wk then per etiology
- cardiac MRI baseline and at 3 mo for inflammation resolution vs fibrotic progression (Klein JASE 2013)
- CRP q1 2 wk target normalisation per ICAP (PMID 23992557)
- pericardial fluid analysis cell count cytology ADA IGRA Xpert AFB culture glucose LDH protein (ESC 2015)
- pericardial biopsy if etiology unclear or persistent inflammation (ESC 2015)
- serial RHC for constrictive physiology dip and plateau at 3 and 6 mo if symptomatic
- HAS BLED at each NSAID visit for GI bleed risk
- eGFR baseline then per NSAID continuation
- hepatic panel if methotrexate rescue used
- TB workup results AFB culture Xpert pericardial fluid and sputum if TB suspected
- multidisciplinary pericardial team handoff to cardiothoracic surgery if persistent symptoms at 3 to 6 mo

Setting (outpatient) monitoring:
- Echo at 1, 3, 6, 12 mo then annually × 5 yr
- Cardiac MRI at 3 + 12 mo
- CRP/ESR per follow-up
- eGFR + LFT per medication continuation
- RHC if symptomatic constriction + non-invasive equivocal

Follow-up plan: Long-term cardiology + cardiothoracic surgery + etiology-specific specialist follow-up; pericardiectomy if symptomatic constriction persists at 6 mo despite optimal medical therapy (ESC 2015 Class IIa)
- Close-out criterion: long-term follow-up plan + pericardiectomy decision documented

Monitoring phase: Re-accumulation surveillance (echo q24-48h × 7d then weekly); CRP trend (target normalisation per ICAP); MRI repeat at 3 mo to assess inflammation resolution vs fibrotic progression; serial RHC if symptomatic constriction develops

Disposition

Current setting: outpatient — Long-term surveillance + pericardiectomy decision at 3-6 mo if refractory; etiology-specific therapy completion; NSAID/colchicine taper per ICAP; serial echo + cardiac MRI; multidisciplinary continuation (ESC 2015; Sagristà-Sauleda NEJM 2004 PMID 15128896)

Disposition criteria:
- Long-term continuation under multidisciplinary team; pericardiectomy if chronic refractory constriction at 3-6 mo; cross-link to cardio.cardiac-tamponade.core.v1 for acute recurrence pathway

Escalation triggers (move to higher acuity):
- Symptomatic chronic constrictive pericarditis (NYHA II-IV with constrictive physiology on imaging) despite 3-6 mo optimal medical therapy → cardiothoracic surgery for pericardiectomy (ESC 2015 Class IIa)
- Radiation etiology — typically fibrotic + irreversible — earlier pericardiectomy referral
- TB etiology — complete RIPE 4-6 mo before pericardiectomy decision unless decompensated
- Recurrent effusion → re-drainage + diagnostic reconsideration
- NSAID-related GI bleed → hold + reverse

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] After pericardiocentesis evacuates fluid, hemodynamic decompensation occurs — residual visceral constriction limits diastolic filling; clinical correlate of effusive-constrictive physiology that requires bridging therapy + urgent cardiothoracic surgery evaluation
- [SEVERE] After pericardiocentesis, RA pressure fails to fall ≥50% or to <10 mmHg despite normalisation of intrapericardial pressure → effusive-constrictive physiology confirmed (Sagristà-Sauleda NEJM 2004 PMID 15128896)
- [SEVERE] Radiation-induced effusive-constrictive pericarditis with persistent symptoms — radiation substrate is typically fibrotic and irreversible; pericardiectomy operative mortality is HIGHER in radiation field (mediastinal fibrosis, vascular adhesions); requires careful surgical evaluation by experienced pericardial surgery team

Citations

- Sagristà-Sauleda J et al. NEJM 2004 PMID 15128896 — diagnostic hemodynamic definition of effusive-constrictive pericarditis (sentinel paper); 2015 ESC Pericardial Diseases (Adler EHJ 2015 PMID 26320112) §3.5 anchors management pathway including pericardiectomy decision criteria; ICAP (Imazio NEJM 2013 PMID 23992557) anchors NSAID + colchicine for inflammatory etiology; IMPI (Mayosi NEJM 2014 PMID 25199187) anchors steroid decision in TB etiology by HIV status; WHO TB 2024 anchors RIPE 4-drug regimen if TB etiology; Klein JASE 2013 anchors multimodality pericardial imaging; Murashita JTCVS Mayo experience anchors pericardiectomy operative outcomes. [PMID:15128896](https://pubmed.ncbi.nlm.nih.gov/15128896/)
- Cited evidence (PMID 26320112) [PMID:26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/)
- Cited evidence (PMID 23992557) [PMID:23992557](https://pubmed.ncbi.nlm.nih.gov/23992557/)
- Cited evidence (PMID 21788540) [PMID:21788540](https://pubmed.ncbi.nlm.nih.gov/21788540/)
- Cited evidence (PMID 24239018) [PMID:24239018](https://pubmed.ncbi.nlm.nih.gov/24239018/)

Last reconciled with current guidelines: 2026-05-15.
References
  • Sagristà-Sauleda J et al. NEJM 2004 PMID 15128896 — diagnostic hemodynamic definition of effusive-constrictive pericarditis (sentinel paper); 2015 ESC Pericardial Diseases (Adler EHJ 2015 PMID 26320112) §3.5 anchors management pathway including pericardiectomy decision criteria; ICAP (Imazio NEJM 2013 PMID 23992557) anchors NSAID + colchicine for inflammatory etiology; IMPI (Mayosi NEJM 2014 PMID 25199187) anchors steroid decision in TB etiology by HIV status; WHO TB 2024 anchors RIPE 4-drug regimen if TB etiology; Klein JASE 2013 anchors multimodality pericardial imaging; Murashita JTCVS Mayo experience anchors pericardiectomy operative outcomes. — PMID:15128896
  • Cited evidence (PMID 26320112) — PMID:26320112
  • Cited evidence (PMID 23992557) — PMID:23992557
  • Cited evidence (PMID 21788540) — PMID:21788540
  • Cited evidence (PMID 24239018) — PMID:24239018